CA
Caris Life Sciences, Inc.
CAI · NASDAQ
$28.50 +10.47% (+$2.70)
1M +31.76%
Market Cap $8.06B
P/E Ratio 76.63x
Div. Yield -
ROE 18.77%
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive P/E 76.63x
P/B 13.61x
EV/EBITDA 45.27x
Growth
100 /100
Growing Rev. growth 46.46%
EPS growth N/A
Book val. growth N/A
Profitability
79 /100
Strong Gross margin 69.66%
FCF margin 14.80%
Net margin 10.62%
Quality
79 /100
Excellent ROIC 14.69%
Asset turnover 0.80x
ROE 18.77%
Debt
78 /100
Low Debt/Equity 0.76x
Net debt/EBITDA -1.38x
Current ratio 5.53x
Stability
41 /100
Moderate Beta 0.68x
Profitable years 0
Rev. volatility 41.46%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na CAI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Dean Halbert
Employees
1,846
Headquarters
Irving
Nadcházející události
04 LIS
Earnings
Upcoming earnings report